Rheumatoid arthritis: Biologics in second-line therapy show benefit, study suggests

Scientists examined nine biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis for whom prior pharmacological treatment had failed. According to the findings, for each drug the data provided proof, an indication, or at least a hint of a benefit in relation to at least one outcome criterion.

Read the whole article on Science Daily

More from Science Daily